NCT06756126

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

A Multicenter, Open Label Phase II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AK120 in Adolescents With Moderate-to-severe AD

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 12 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis

Detailed description

This is a A multicenter, open label, phase II clinical study aimed to evaluate the safety, PK, PD, and preliminary efficacy of AK120 in adolescents with moderate-to-severe AD. The entire study include screening period(week -4 to week 0), treatment and follow-up period(16 weeks). The duration of the study is about 20 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	AK120	AK120 subcutaneous injection

Timeline

• Start date: 2024-12-30
• Primary completion: 2025-06-30
• Completion: 2025-06-30
• First posted: 2025-01-01
• Last updated: 2025-01-01

Locations

6 sites across 1 country: China